By Michael Erman NEW YORK (Reuters) - Mylan NV said on Tuesday that U.S. consumers may have difficulty getting EpiPen prescriptions filled after manufacturing problems constrained supply, but the drugmaker did not say there was a shortage of its emergency allergy treatment. This was Mylan's first acknowledgment of possible U.S. supply issues following reports of EpiPen shortages in Canada and Britain last month. Shares of Mylan, which is due to report quarterly financial results on Wednesday, fell 2 percent to $35.37.
from Yahoo News - Latest News & Headlines https://ift.tt/2I5l9nd
May 09, 2018 at 04:04AM
Comments
Post a Comment